Avalo Therapeutics (Avalo Therapeutics) Days Inventory : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Avalo Therapeutics Days Inventory?

Days Inventory is also known as Days Sales of Inventory (DSI). Avalo Therapeutics's Average Total Inventories for the three months ended in Dec. 2023 was $0.00 Mil. Avalo Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was $-0.22 Mil.

The historical rank and industry rank for Avalo Therapeutics's Days Inventory or its related term are showing as below:

AVTX' s Days Inventory Range Over the Past 10 Years
Min: 3.08 Med: 10.15 Max: 219.23
Current: 5.61

During the past 11 years, Avalo Therapeutics's highest Days Inventory was 219.23. The lowest was 3.08. And the median was 10.15.

AVTX's Days Inventory is ranked better than
98.31% of 649 companies
in the Biotechnology industry
Industry Median: 191.36 vs AVTX: 5.61

Avalo Therapeutics's Days Inventory declined from Dec. 2022 (3.09) to Dec. 2023 (0.00).

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Avalo Therapeutics's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.00.

Avalo Therapeutics Days Inventory Historical Data

The historical data trend for Avalo Therapeutics's Days Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avalo Therapeutics Days Inventory Chart

Avalo Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Inventory

Get a 7-Day Free Trial

14.60

5.02

3.08

5.69

Avalo Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Inventory	Get a 7-Day Free Trial															3.09	3.23	2.38	6.65	-

Competitive Comparison of Avalo Therapeutics's Days Inventory

For the Biotechnology subindustry, Avalo Therapeutics's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics's Days Inventory Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Days Inventory distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Days Inventory falls into.

Avalo Therapeutics Days Inventory Calculation

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Avalo Therapeutics's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as

	Days Inventory (A: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.02	+	0)	/	1 )	/	1.284	*	365
=	0.02					/	1.284	*	365
=	5.69

Avalo Therapeutics's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:

	Days Inventory (Q: Dec. 2023 )
=	Average Total Inventories					/	Cost of Goods Sold	*	Days in Period
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	-0.221	*	365 / 4
=	0					/	-0.221	*	365 / 4
=	N/A

Avalo Therapeutics (NAS:AVTX) Days Inventory Explanation

Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:

1. Inventory Turnover measures how fast the company turns over its inventory within a year.

Avalo Therapeutics's Inventory Turnover for the three months ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	-0.221	/	0
	=

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Avalo Therapeutics's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0.571
	=	0.00

Be Aware

A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.

Avalo Therapeutics Days Inventory Related Terms

Thank you for viewing the detailed overview of Avalo Therapeutics's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Avalo Therapeutics (Avalo Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avalo Therapeutics Inc (NAS:AVTX) » Definitions » Days Inventory

Comparable Companies

Traded in Other Exchanges

C6K0:Germany C6K0:Germany

Address

540 Gaither Road, Suite 400, Rockville, MD, USA, 20850

Website

https://www.avalotx.com

Avalo Therapeutics Inc is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Its pipeline consists of product candidates advancing in development with ongoing clinical programs: AVTX-002, AVTX-007, and AVTX-006.

Executives

Armistice Capital Master Fund Ltd.	director, 10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Caissa Capital Management Ltd.	10 percent owner	PALM GROVE HOUSE, WICKHAMS CAY 1 ROAD TOWN, TORTOLA D8 VG1110
Christopher Ryan Sullivan	officer: Interim CFO	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Garry Arthur Neil	officer: Chief Medical Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Mitchell Chan	director	C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO, GAITHERSBURG MD 20878
Stephen Smolinski	officer: Chief Commercial Officer	C/O SELECTA BIOSCIENCES, INC., 480 ARSENAL WAY, WATERTOWN MA 02472
Magnus Persson	director	400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Joseph M Miller	director	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Gilla Kaplan	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
June Sherie Almenoff	director	C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Schond L. Greenway	officer: CFO & Treasurer	C/O CERECOR, INC., 540 GAITHER ROAD, SUITE 400, ROCKVILLE MD 20850
H Jeffrey Wilkins	officer: Chief Medical Officer	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Harrell James Archie Jr	officer: Chief Commercial Officer	C/O CERECOR INC., 400 E. PRATT STREET, SUITE 606, BALTIMORE MD 21202
Illya Keith Maher	director	C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	director, 10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022